Espat N J, Brennan M F, Conlon K C
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
J Am Coll Surg. 1999 Jun;188(6):649-55; discussion 655-7. doi: 10.1016/s1072-7515(99)00050-2.
Laparoscopic staging is an effective and accurate means of staging pancreatic cancer. But, the frequency of subsequent surgical bypass to treat biliary or gastric obstruction in laparoscopically staged patients with unresectable adenocarcinoma is unknown. The development of biliary and gastric obstruction in patients with unresectable pancreatic adenocarcinoma has been reported to occur in as many as 70% and 25% of patients, respectively. Previously, staging for patients with pancreatic cancer was achieved by laparotomy and the anticipated high rate for these patients to develop obstruction led to prophylactic bypass procedures. As laparoscopic staging for pancreatic cancer becomes a standard modality, the need for prophylactic bypass procedures in these patients needs to be examined.
Analyses of laparoscopically staged patients (n = 155) with unresectable, histologically proved pancreatic adenocarcinoma, from a single institution treated between 1993-1997 were performed. The frequency of surgical bypass in a prospective cohort of patients with unresectable pancreatic adenocarcinoma who did not undergo open enteric or biliary bypass at the time of laparoscopic staging was determined.
Laparoscopic staging revealed that 40 patients had locally advanced disease and 115 had metastatic disease. Median survival for patients with locally advanced and metastatic disease was 6.2 and 7.8 months, respectively. Postlaparoscopy followup revealed that 98% (152 of 155) of these patients did not require a subsequent open surgical procedure to treat biliary or gastric obstruction.
These results do not support the practice of routine prophylactic bypass procedures. As such, we propose that surgical biliary bypass can be advocated only for those patients with obstructive jaundice who fail endoscopic stent placement, and gastroenterostomy should be reserved for patients with confirmed gastric outlet obstruction.
腹腔镜分期是胰腺癌分期的一种有效且准确的方法。但是,对于腹腔镜分期为不可切除腺癌的患者,后续行手术旁路治疗胆道或胃梗阻的频率尚不清楚。据报道,不可切除胰腺腺癌患者中,分别有多达70%和25%会出现胆道和胃梗阻。以前,胰腺癌患者通过剖腹手术进行分期,鉴于这些患者发生梗阻的预期高发生率,因此采取了预防性旁路手术。随着腹腔镜胰腺癌分期成为一种标准方式,需要对这些患者进行预防性旁路手术的必要性进行研究。
对1993年至1997年间在单一机构接受治疗的155例经组织学证实为不可切除胰腺腺癌且接受腹腔镜分期的患者进行分析。确定了一组前瞻性不可切除胰腺腺癌患者在腹腔镜分期时未进行开放式肠道或胆道旁路手术的情况下进行手术旁路的频率。
腹腔镜分期显示,40例患者为局部晚期疾病,115例为转移性疾病。局部晚期和转移性疾病患者的中位生存期分别为6.2个月和7.8个月。腹腔镜检查后的随访显示,这些患者中有98%(155例中的152例)不需要后续的开放式手术来治疗胆道或胃梗阻。
这些结果不支持常规预防性旁路手术的做法。因此,我们建议仅对那些内镜支架置入失败的梗阻性黄疸患者提倡手术胆道旁路,胃造口术应仅用于确诊为胃出口梗阻的患者。